Eyenovia Inc. filed for an IPO of up to $35 million of its common stock.
The company has applied to list its common stock on the Nasdaq Capital Market under the symbol EYEN.
Net proceeds will be used to complete phase 3 clinical trials of company's products MicroProst and MicroStat, registration activities for MicroTears, and to complete scale-up engineering and manufacturing for pivotal trials and approval from the U.S. Food and Drug Administration. The proceeds will also be used for the completion of formulation work for each development program and for general corporate purposes, including working capital.
Eyenovia is a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-doses of active pharmaceutical ingredients, or micro-therapeutics, topically to the eye.
Ladenburg Thalmann & Co. Inc. and Roth Capital Partners LLC will act as underwriters for the offering.